Weekly Research Analysts’ Ratings Updates for Scholar Rock (SRRK)

A number of firms have modified their ratings and price targets on shares of Scholar Rock (NASDAQ: SRRK) recently:

• 1/9/2026 – Scholar Rock is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $55.00 price target on the stock.
• 1/9/2026 – Scholar Rock is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $55.00 price target on the stock.
• 1/7/2026 – Scholar Rock is now covered by analysts at UBS Group AG. They set a “buy” rating and a $60.00 price target on the stock.
• 1/7/2026 – Scholar Rock is now covered by analysts at UBS Group AG. They set a “buy” rating and a $60.00 price target on the stock.
• 12/17/2025 – Scholar Rock had its price target raised by analysts at Barclays PLC from $45.00 to $52.00. They now have an “overweight” rating on the stock.
• 12/11/2025 – Scholar Rock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.

Insider Transactions at Scholar Rock

In related news, CEO David Hallal sold 57,450 shares of the stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $2,453,115.00. Following the sale, the chief executive officer owned 1,541,645 shares of the company’s stock, valued at approximately $65,828,241.50. This represents a 3.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Caryn Parlavecchio sold 6,600 shares of Scholar Rock stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $44.48, for a total value of $293,568.00. Following the sale, the insider owned 148,864 shares of the company’s stock, valued at approximately $6,621,470.72. This trade represents a 4.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 290,789 shares of company stock valued at $12,844,688. 13.30% of the stock is currently owned by insiders.

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).